Fig. 2.

SARS-CoV-2 PLpro exhibits multiple potential therapeutic hotspots. (A) X-ray crystal structure of SARS-CoV-2 PLpro shown in cartoon, with the illustration of fingers, palm, thumb and ubiquitin-like (UL) domains (PDB ID 6wuu). The catalytic residues are displayed with green sticks and the two ubiquitin-binding sites (UBS1 and UBS2) are colored blue and purple, respectively. (B) The structure of SARS-CoV-2 PLpro overlaid by its complex with the dual action inhibitor, GRL0617 showing the interactions of the inhibitor with Tyr-268 that has adopted different conformation in the complex structure (PDBID 7jir). (C) Chemical structures of different SARS-CoV-2 PLpro inhibitors.